Arovella Therapeutics Limited AI Stock Analysis
Want to see AU:ALA full AI Analyst Report?
Arovella Therapeutics Limited (ALA) AI Stock Analysis
Arovella Therapeutics Limited
(ASX:ALA)
The score is primarily weighed down by weak financial performance (minimal/unstable revenue, ongoing losses, and continued cash burn). Technicals further detract due to a clear downtrend and bearish momentum signals. Valuation offers limited support because the company is loss-making (negative P/E) and there is no dividend yield data.
Arovella Therapeutics Limited (ALA) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 60.44M
- Dividend Yield
- ―
- Average Volume (3M)
- 679.60K
- Price to Earnings (P/E)
- -8.8
- Beta (1Y)
- 1.52
- Revenue Growth
- -100.00%
- EPS Growth
- 14.71%
- Country
- Australia
- Employees
- 27
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Arovella Therapeutics Limited Business Overview & Revenue Model
Company Description
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key...
Arovella Therapeutics Limited Financial Statement Overview
Summary
Overall financials reflect an early-stage, funding-dependent biotech. The income statement is very weak (immaterial/volatile revenue, large recurring operating and net losses), and cash flow shows persistent operating and free cash flow burn. The main offset is a relatively supportive balance sheet with minimal debt and positive equity, which helps near-term solvency but does not resolve ongoing cash consumption risk.
Income Statement
12Very NegativeBalance Sheet
58NeutralCash Flow
28Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 136.00K | 17.00K | 405.90K | 295.81K |
| Gross Profit | -117.71K | -117.71K | 136.00K | -25.98K | -3.00M | 88.75K |
| EBITDA | -11.10M | -11.10M | -11.10M | -10.63M | -10.37M | -7.87M |
| Net Income | -6.92M | -6.92M | -7.51M | -8.75M | -10.18M | -8.62M |
Balance Sheet | ||||||
| Total Assets | 15.01M | 15.01M | 21.60M | 13.28M | 5.47M | 9.21M |
| Cash, Cash Equivalents and Short-Term Investments | 14.35M | 14.35M | 20.88M | 12.71M | 5.18M | 6.07M |
| Total Debt | 0 | 0 | 0 | 0 | 144.80K | 144.80K |
| Total Liabilities | 857.45K | 857.45K | 1.52M | 2.06M | 1.69M | 1.60M |
| Stockholders Equity | 14.15M | 14.15M | 20.08M | 11.23M | 3.78M | 7.62M |
Cash Flow | ||||||
| Free Cash Flow | -6.95M | -6.95M | -7.34M | -7.04M | -6.40M | -6.83M |
| Operating Cash Flow | -6.91M | -6.91M | -6.93M | -6.91M | -6.40M | -6.27M |
| Investing Cash Flow | -40.48K | -40.48K | -432.11K | -179.34K | 95.42K | -566.00K |
| Financing Cash Flow | 488.69K | 488.69K | 15.52M | 14.61M | 5.41M | 6.19M |
Arovella Therapeutics Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALA, the sentiment is Negative. The current price of 0.05 is above the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 38.92 is Neutral, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ALA.
Arovella Therapeutics Limited Peers Comparison
Overall Rating
AU:RCE46Neutral
AU:RAD42Neutral- AU:ALA41Neutral
AU:IMU39Underperform
AU:IMM38Underperform
AU:PTX37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:RCE | 46Neutral | AUD 105.52M | -6.95 | 84.67% | ― | ― | 42.51% |
| AU:RAD | 42Neutral | AUD 18.84M | -0.26 | -144.24% | ― | -23.82% | 12.36% |
| AU:ALA | 41Neutral | AUD 60.44M | -8.79 | -41.83% | ― | -100.00% | 14.71% |
| AU:IMU | 39Underperform | AUD 19.78M | -0.11 | -414.10% | ― | ― | -2.15% |
| AU:IMM | 38Underperform | AUD 35.38M | -0.46 | -98.86% | ― | ― | -27.73% |
| AU:PTX | 37Underperform | AUD 68.63M | -9.13 | -44.93% | ― | ― | 25.27% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:ALA | Arovella Therapeutics Limited | 0.05 | -0.04 | -44.57% | |
| AU:IMU | Imugene Ltd | 0.03 | -0.28 | -89.03% | |
| AU:IMM | Immutep Ltd | 0.03 | -0.24 | -90.38% | |
| AU:PTX | Prescient Therapeutics Limited | 0.06 | 0.01 | 29.17% | |
| AU:RAD | Radiopharm Theranostics Limited | 0.01 | -0.01 | -56.52% | |
| AU:RCE | Recce Pharmaceuticals Ltd. | 0.36 | -0.09 | -19.10% |
Arovella Therapeutics Limited Corporate Events
Arovella doses first patient in phase 1 trial of off-the-shelf cell therapy ALA-101
Arovella Therapeutics has reached a key milestone by dosing the first patient in its phase 1 SAPPHIRE clinical trial of ALA-101, an off-the-shelf allogeneic CD19 CAR-iNKT cell therapy for relapsed or refractory CD19-positive non-Hodgkin lymphoma and...
Arovella Advances Off-the-Shelf CAR-iNKT Trials as Cash Position Strengthens
Arovella Therapeutics has reached clinical readiness for its lead CD19-targeting CAR-iNKT cell therapy, ALA-101, releasing two GMP-manufactured clinical batches and activating two trial sites that have begun screening patients. The first-in-human stu...
Arovella boosts off-the-shelf CAR-iNKT trial readiness with second clinical batch release
Arovella Therapeutics has manufactured and released a second clinical batch of its donor-derived CAR-iNKT therapy ALA-101, demonstrating the reproducibility and scalability of its off-the-shelf manufacturing process. Together with a planned third bat...
Arovella Showcases iNKT Cell Therapy Platform at Major Cell and Gene Meeting
Arovella Therapeutics will present an Innovation Spotlight at the Cell and Gene Meeting on the Mesa in Phoenix, a leading global conference for the cell and gene therapy sector. The session, delivered by acting CEO Dr Nicole van der Weerden, gives th...
Arovella Nears First Patient Dosing in Pivotal ALA-101 Cell Therapy Trial
Arovella Therapeutics is advancing an iNKT cell therapy platform aimed at treating blood cancers, solid tumours and autoimmune disease, with its lead candidate ALA-101 designed as an allogeneic CAR19-iNKT therapy targeting CD19 and CD1d. The company...
Arovella Deepens ESG Commitment Ahead of Australia’s Sustainability Rules
Arovella Therapeutics has released its fifth Environmental, Social, and Governance report, underscoring its commitment to using ESG principles to build long‑term enterprise value and align with United Nations Sustainable Development Goals. The compan...
Arovella Sets Hybrid 2026 AGM and Shifts to Default Digital Communications
Arovella Therapeutics has called its 2026 Annual General Meeting for 11:00 a.m. AEDT on 4 November 2026, offering both online participation via the Automic investor portal and an in‑person option at the offices of MinterEllison in Melbourne. The comp...
Arovella Details Governance Framework in 2026 Corporate Statement
Arovella Therapeutics has released its Corporate Governance Statement for the year ended 30 June 2026, outlining adherence to the ASX Corporate Governance Principles and Recommendations. The document details the roles of the board and management, boa...
Arovella lodges 2026 corporate governance statement and Appendix 4G
Arovella Therapeutics Limited, an ASX-listed biotechnology company, underscores structured governance through formal board and management roles, written agreements with directors and executives, and an online governance portal. The company highlights...
Arovella Narrows Annual Loss as Net Tangible Assets Per Share Fall
Arovella Therapeutics Limited reported a net loss after tax of $6.9 million for the year ended 30 June 2026, an improvement from the $7.5 million loss recorded in the prior year. The company’s revenues from ordinary activities fell to zero, underscor...
Arovella Issues 9.7 Million Unquoted Options Under Employee Incentive Scheme
Arovella Therapeutics Limited has issued 9,749,387 unquoted options under its employee incentive scheme, with various exercise prices and expiry dates, effective 17 August 2026. The move expands the company’s pool of employee equity incentives, reinf...
Arovella outlines strategy and ALA-101 trial timeline in investor webinar
Arovella Therapeutics will host an investor webinar today to brief shareholders and the market on the outcomes of its recent strategic review and priorities for advancing its iNKT cell therapy platform. The session will outline near-term clinical dev...
Arovella plans investor webinar ahead of first-in-human ALA-101 trial
Arovella Therapeutics will host an investor webinar to update shareholders and market participants on the Board’s recent strategic review and priorities for advancing its iNKT cell therapy platform. The event will outline near-term clinical developme...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 29, 2026